In a 55‑year‑old woman with generalized anxiety disorder and a current severe mixed bipolar episode with psychotic features who is taking trazodone 100 mg at bedtime, lamotrigine (Lamictal) 100 mg twice daily, hydroxyzine 25 mg every six hours as needed (to be discontinued tomorrow), and quetiapine 50 mg twice daily, which buspirone dosing regimen—5 mg twice daily, 5 mg three times daily, or 10 mg twice daily—is most appropriate for her high anxiety?

Buspirone Dosing Recommendation

Start with buspirone 5 mg twice daily (BID) and titrate gradually to 10 mg BID over 1-2 weeks, rather than initiating at 10 mg BID or using three-times-daily dosing. This approach balances efficacy with tolerability in your patient with severe mixed bipolar disorder and high anxiety.

Rationale for This Recommendation

Starting Dose and Titration Strategy

The FDA-approved buspirone labeling 1 and clinical guidelines 2 consistently recommend an initial dosage of 5 mg twice daily, with a maximum of 20 mg three times daily (60 mg/day total). The standard approach involves:

• Initial dose: 5 mg BID (10 mg/day total)
• Titration: Increase by 5 mg/day every 2-3 days as tolerated
• Target dose for GAD: Typically 15-30 mg/day in divided doses
• Maximum: 60 mg/day

For your patient with "high, high anxiety," starting at 5 mg BID allows you to assess tolerability before escalating, which is particularly important given her complex medication regimen.

Why Not 10 mg BID Initially?

Starting at 10 mg BID (20 mg/day) bypasses the recommended titration and increases the risk of:

• Dizziness and lightheadedness (common early side effects)
• Nausea
• Headache
• Poor adherence due to initial side effects

The key clinical caveat: Buspirone requires 2-4 weeks to become effective 2, so there is no therapeutic advantage to starting at a higher dose—you won't achieve faster anxiety relief, only more side effects.

Why Not 5 mg TID?

While 5 mg three times daily (15 mg/day total) is within the therapeutic range, twice-daily dosing improves adherence and is simpler for patients already on multiple medications. Your patient is currently taking:

• Trazodone (once daily at bedtime)
• Lamotrigine (BID)
• Quetiapine (BID)
• Hydroxyzine (q6h PRN, ending tomorrow)

Adding another TID medication increases complexity unnecessarily when BID dosing can achieve the same total daily dose with better compliance.

Critical Considerations for This Patient

Bipolar Disorder Context

Your patient has severe mixed bipolar disorder with psychotic features. This is crucial because:

1. Buspirone lacks antimanic properties 3, 4—it will not destabilize her mood or induce mania, unlike some antidepressants
2. Buspirone is NOT an antipsychotic 1—the FDA label explicitly warns it "has no established antipsychotic activity" and "should not be employed in lieu of appropriate antipsychotic treatment"
3. Her current quetiapine dose (50 mg BID = 100 mg/day) is subtherapeutic for psychosis—typical antipsychotic doses for acute psychosis range from 300-800 mg/day 2

Important pitfall: Do not rely on buspirone to address her psychotic symptoms or mood instability. Her quetiapine dose may need optimization separately.

Drug Interactions and Safety

Serotonin syndrome risk 1: Buspirone is serotonergic and your patient is on:

• Trazodone (serotonergic antidepressant)
• Quetiapine (weak serotonin activity)

While the risk is low at therapeutic doses, monitor for: agitation, confusion, tremor, tachycardia, diaphoresis, or myoclonus, especially during the first 2 weeks of buspirone initiation.

No significant interactions with lamotrigine or hydroxyzine 1.

Transitioning from Hydroxyzine

Since hydroxyzine ends tomorrow, there will be a 2-4 week gap before buspirone reaches full efficacy 2. During this transition period:

• Consider short-term PRN strategies if breakthrough anxiety is severe
• Educate the patient that buspirone is not "as-needed" medication—it requires daily dosing for weeks to work
• The quetiapine may provide some interim anxiolytic effect, though at her current dose this is modest

Practical Dosing Algorithm

Week 1-2: Buspirone 5 mg BID (morning and evening)

• Assess tolerability
• Educate patient about delayed onset of action

Week 3: If tolerated, increase to 7.5 mg BID (using scored tablets)

• Alternative: Increase to 10 mg BID if no side effects and anxiety remains severe

Week 4-6: Target dose 10-15 mg BID (20-30 mg/day total)

• Most patients with GAD respond in this range 5, 6
• Maximum 20 mg TID (60 mg/day) if needed, though rarely necessary

Reassess at 6-8 weeks: Full therapeutic trial requires at least 4-6 weeks at target dose 6, 7

Alternative Considerations

Recent evidence 5 suggests that in older adults (your patient is 55), SSRIs remain first-line for GAD, with buspirone reserved for patients prioritizing avoidance of sexual side effects or in "relatively healthy" individuals. However, given your patient's bipolar disorder, SSRIs carry risk of mood destabilization and would require careful mood stabilizer coverage—her current lamotrigine 100 mg BID may be insufficient for this purpose 3, 4.

Buspirone is a reasonable choice here because it:

• Does not induce mania
• Has no abuse potential (unlike benzodiazepines)
• Lacks sedation (unlike increasing quetiapine)
• Provides antidepressant augmentation properties in some patients 6

Common Pitfalls to Avoid

1. Don't expect immediate results: Counsel the patient that buspirone takes 2-4 weeks to work, unlike the hydroxyzine she's been using PRN
2. Don't use buspirone PRN: It must be taken daily on schedule
3. Don't discontinue abruptly: Though not associated with withdrawal syndrome like benzodiazepines, taper if discontinuing after prolonged use
4. Don't rely on buspirone for psychosis management: Address her subtherapeutic quetiapine dose separately if psychotic symptoms persist